We are live on ! Find out more
Stonepine Capital Management

Stonepine Capital Management Portfolio holdings

AUM $159M Turnover 51.35%
1-Year Est. Return 62.27%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+62.27%
3 Year Est. Return
+321.39%
5 Year Est. Return
+335.25%
10 Year Est. Return
+1,440.6%
AUM
$97.5M
AUM Growth
+$12.7M
Cap. Flow
-$2.23M
Cap. Flow %
-2.29%
Top 10 Hldgs %
80.62%
Holding
30
New
10
Increased
6
Reduced
5
Closed
7
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.3 years
Top 20 Avg Time Held
0.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 70.89%
2 Miscellaneous 29.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SCLN
1
DELISTED
Sciclone Pharmaceuticals
SCLN
$14.1M 14.5%
1,082,532
-966,106
-47% -$12.7M
2015 Q4
2 quarters
VNDA icon
2
Vanda Pharmaceuticals
VNDA
$223M
$9.08M 9.31%
811,563
-1,256,734
-61% -$12.2M
2015 Q4
2 quarters
TBRA
3
DELISTED
Tobira Therapeutics
TBRA
$8.01M 8.21%
637,567
-195,410
-23% -$1.82M
2015 Q4
2 quarters
FLNA icon
4
Filana Therapeutics
FLNA
$27.7M
$6.22M 6.37%
405,411
-98,932
-20% -$1.57M
2015 Q4
2 quarters
QLTI icon
5
DELISTED
QLT Inc
QLTI
$5.37M 5.5%
+3,779,274
New +$5.81M
2016 Q2
0 quarters
SGNT
6
DELISTED
Sagent Pharmaceuticals
SGNT
$5.34M 5.47%
356,307
+23,242
+7% +$299K
2015 Q4
2 quarters
VCEL icon
7
Vericel
VCEL
$2.98B
$5.06M 5.19%
2,250,000
+832,061
+59% +$2.4M
2015 Q4
2 quarters
CUTR icon
8
DELISTED
Cutera
CUTR
$4.91M 5.03%
438,000
+65,700
+18% +$721K
2015 Q4
2 quarters
SCTL
9
DELISTED
Societal CDMO
SCTL
$3.41M 3.49%
477,967
+213,852
+81% +$1.43M
2015 Q4
2 quarters
ALR
10
DELISTED
Alere Inc
ALR
$3.13M 3.2%
+75,000
New +$3.25M
2016 Q2
0 quarters
SCMP
11
DELISTED
Sucampo Pharmaceuticals
SCMP
$2.35M 2.41%
213,860
+208,632
+3,991% +$2.34M
2016 Q1
1 quarter
PCRX icon
12
Pacira BioSciences
PCRX
$1.76M 1.8%
+52,157
New +$2.56M
2016 Q2
0 quarters
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$1.38M 1.41%
+128,005
New +$1.36M
2016 Q2
0 quarters
BSTC
14
DELISTED
BioSpecifics Technologies
BSTC
$1.2M 1.23%
30,000
+4,363
+17% +$160K
2016 Q1
1 quarter
DSCI
15
DELISTED
Derma Sciences
DSCI
$1.12M 1.14%
283,306
-224,493
-44% -$839K
2015 Q4
2 quarters
VCYT icon
16
Veracyte
VCYT
$2.12B
$940K 0.96%
+186,926
New +$1M
2016 Q2
0 quarters
CPIX icon
17
Cumberland Pharmaceuticals
CPIX
$101M
$580K 0.59%
+128,798
New +$590K
2016 Q2
0 quarters
VXRT icon
18
DELISTED
Vaxart
VXRT
$412K 0.42%
+26,752
New +$445K
2016 Q2
0 quarters
DRRX icon
19
DELISTED
DURECT Corp
DRRX
$98K 0.1%
+8,016
New +$103K
2016 Q2
0 quarters
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.59B
– –
-1,650
Closed -$56K –
INSY
21
DELISTED
Insys Therapeutics
INSY
– –
-2,000
Closed -$32K –
ZLTQ
22
DELISTED
Zeltiq Aesthetics
ZLTQ
– –
-70,000
Closed -$1.9M –
PTX
23
DELISTED
Pernix Therapeutics Holdings
PTX
– –
-321,586
Closed -$3.38M –
CTIC
24
DELISTED
CTI BioPharma
CTIC
– –
-374,334
Closed -$1.99M –
BDSI
25
DELISTED
BioDelivery Sciences International
BDSI
– –
-8,523
Closed -$28K –

Similar funds

Stonepine Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Stonepine Capital Management held 30 positions worth $97.5M, up 15% from $84.8M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Stonepine Capital Management's Q2 2016 filing shows 10 new, 6 increased, 5 reduced and 7 closed positions. Its largest new stake was QLT Inc: 3,779,274 shares worth $5.37M. The largest sale was Sciclone Pharmaceuticals, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 92% a quarter earlier, followed by Miscellaneous.

  • Stonepine Capital Management's largest Q2 2016 buy was QLT Inc: 3,779,274 shares worth $5.37M.
  • Stonepine Capital Management added most to Vericel in Q2 2016, an estimated $2.4M increase.
  • Stonepine Capital Management's biggest Q2 2016 reduction was Sciclone Pharmaceuticals, cutting an estimated $12.7M.
  • Stonepine Capital Management fully exited Pernix Therapeutics Holdings in Q2 2016, selling an estimated $3.38M.
  • Stonepine Capital Management's ten largest holdings make up 81% of its $97.5M portfolio in Q2 2016.
  • Stonepine Capital Management opened 10 new positions and closed 7 in Q2 2016.
  • Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $97.5M.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.